Sofosbuvir-based therapy successfully treats HCV patients with decompensated liver disease, according to a new study.
New research finds direct-acting antivirals can be given safely to those on liver transplant waitlist.
Hepatitis C virus infection in liver transplant recipients can be treated with ledipasvir and sofosbuvir without ribavirin.
A combination of three drugs successfully treats HCV-infected patients with advanced liver disease.
A shorter, triple DAA therapy combination is not superior to 12 weeks of sofosbuvir plus velpatasvir in chronic HCV patients, according to researchers.
New study indicates early recognition of HBV-HCV co-infection can lead to prompt treatment of HBV reactivation.
Multiple oral direct-acting antiviral agents show great promise in treating the vast majority of hepatitis C patients.
The introduction of direct-acting antiviral agents has transformed hepatitis C care among veterans.
Early data shows promise in “real-world” effectiveness.
Physicians have a “good, effective, safe therapy available” for hepatitis C virus genotype 6 patients, says researcher.